LUNGevity is happy to support the AllTrials initiative and its goal of increased clinical trial transparency. With recent advancements and new treatment options for advanced lung cancer patients, there is a real opportunity to improve outcomes for people diagnosed with the disease. LUNGevity believes that industry, academia, clinicians, and regulators must prioritize research and streamline clinical trials to ensure that treatments are accelerated to patients and that patients have access to their data and trial results.